XML 47 R6.htm IDEA: XBRL DOCUMENT v2.4.0.8
CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)
In Thousands, unless otherwise specified
 12 Months Ended
Jan. 31, 2014
Jan. 31, 2013
Jan. 31, 2012
Cash flows from operating activities      
Net income $ 76,402 $ 56,569 $ 49,620
Adjustments to reconcile net income to net cash provided by operating activities, net of assets and liabilities acquired:      
Depreciation and amortization 13,676 9,941 7,473
Equity based compensation 9,953 7,738 5,200
Tax benefit from exercise/vesting of equity awards 2,545 1,378 809
Deferred financing charges 751 500 425
Equity loss in joint venture   719 1,271
Change in contingent purchase price payable (468)    
Deferred income taxes 754 (1,191) 3,568
Gain on sale of joint venture interest   (185)  
Changes in operating assets and liabilities:      
Accounts receivable, net 18,611 (8,249) (24,169)
Inventories, net (35,584) (16,862) (48,526)
Income taxes, net (18,766) 6,114 6,171
Prepaid expenses and other current assets (1,434) (3,824) (1,324)
Other assets, net (14,972) (2,833) 64
Accounts payable, accrued expenses and other liabilities 33,125 4,679 6,194
Net cash provided by operating activities 84,593 54,494 6,776
Cash flows from investing activities      
Acquisitions, net of cash acquired (49,129) (80,252)  
Proceeds from (investment in) equity of joint venture, net   1,885 (3,650)
Capital expenditures (29,283) (11,615) (17,410)
Net cash used in investing activities (78,412) (89,982) (21,060)
Cash flows from financing activities      
(Repayment of) proceeds from notes payable, net (16,157) 34,950 30,050
Noncontrolling interest investment, net 2,399 (883)  
Loss attributable to noncontrolling interest   306  
Proceeds from exercise of equity awards 1,906 1,425 619
Stock repurchase     (2,929)
Taxes paid for net share settlement (1,062)    
Excess tax benefit from exercise/vesting of equity awards 2,915 1,870 1,136
Net cash (used in) provided by financing activities (9,999) 37,668 28,876
Effect of exchange rate changes (1,451) 520 23
Net (decrease) increase in cash and cash equivalents (5,269) 2,700 14,615
Cash and cash equivalents at beginning of year 27,360 24,660 10,045
Cash and cash equivalents at end of year 22,091 27,360 24,660
Cash paid during the year for:      
Interest 8,500 9,996 5,228
Income taxes 65,076 28,615 18,243
Notes issued in connection with the acquisition of Vilebrequin   19,778  
Contingent consideration in connection with the acquisition of Vilebrequin   $ 5,787